1. |
WHO. COVID19情况报告. 2022.
|
2. |
国家卫生健康委员会官方网站. 截至12月4日24时新型冠状病毒肺炎疫情最新情况. 2022.
|
3. |
余悦, 邱晓燕, 钟明康. 新型冠状病毒肺炎治疗药物的最新研发进展. 中国医药工业杂志, 2022, 53(6): 775-784.
|
4. |
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health, 2022, 25(1): 3-9.
|
5. |
Willke RJ, Pizzi LT. CHEERS to updated guidelines for reporting health economic evaluations! Value Health, 2022, 25(1): 1-2.
|
6. |
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force. Value Health, 2022, 25(1): 10-31.
|
7. |
Carta A, Conversano C. Cost utility analysis of remdesivir and dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res, 2021, 21(1): 986.
|
8. |
Oksuz E, Malhan S, Gonen MS, et al. Cost-effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey. Adv Ther, 2021, 38(9): 4935-4948.
|
9. |
Goswami H, Alsumali A, Jiang Y, et al. Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US. Pharmacoeconomics, 2022, 40(7): 699-714.
|
10. |
Kelton K, Klein T, Murphy D, et al. Cost-effectiveness of combination of baricitinib and remdesivir in hospitalized patients with COVID-19 in the United States: a modelling study. Adv Ther, 2022, 39(1): 562-582.
|
11. |
Ruggeri M, Signorini A, Caravaggio S, et al. Estimation model for healthcare costs and intensive care units access for COVID-19 patients and evaluation of the effects of remdesivir in the portuguese context: hypothetical study. Clin Drug Investig, 2022, 42(4): 345-354.
|
12. |
Whittington MD, Pearson SD, Rind DM, et al. The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value Health, 2022, 25(5): 744-750.
|
13. |
Jovanoski N, Kuznik A, Becker U, et al. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. J Manag Care Spec Pharm, 2022, 28(5): 555-565.
|
14. |
Sinha P, Linas BP. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces coronavirus disease 2019 mortality. Clin Infect Dis, 2021, 73(11): 2116-2118.
|
15. |
Rafia R, Martyn-St James M, Harnan S, et al. A cost-effectiveness analysis of remdesivir for the treatment of hospitalized patients with COVID-19 in England and Wales. Value Health, 2022, 25(5): 761-769.
|
16. |
Águas R, Mahdi A, Shretta R, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun, 2021, 12(1): 915.
|
17. |
Ohsfeldt R, Kelton K, Klein T, et al. Cost-effectiveness of baricitinib compared with standard of care: a modeling study in hospitalized patients with COVID-19 in the United States. Clin Ther, 2021, 43(11): 1877-1893.
|
18. |
Chow R, Simone CB, Prsic EH, et al. Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients. Ann Palliat Med, 2022, 11(7): 2285-2290.
|
19. |
Congly SE, Varughese RA, Brown CE, et al. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep, 2021, 11(1): 17787.
|
20. |
Dijk SW, Krijkamp EM, Kunst N, et al. Emerging therapies for COVID-19: the value of information from more clinical trials. Value Health, 2022, 25(8): 1268-1280.
|
21. |
Jiang Y, Cai D, Chen D, et al. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. Br J Clin Pharmacol, 2021, 87(11): 4386-4396.
|
22. |
Jo Y, Jamieson L, Edoka I, et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. Open Forum Infect Dis, 2021, 8(3): ofab040.
|
23. |
Jo Y, Kim SB, Radnaabaatar M, et al. Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea. Epidemiol Health, 2022, 44: e2022034.
|
24. |
Alamer A, Almutairi AR, Halloush S, et al. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals. Saudi Pharm J, 2023, 31(4): 510-516.
|
25. |
Lau VI, Fowler R, Pinto R, et al. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian treatments for COVID-19 (CATCO) randomized clinical trial. CMAJ Open, 2022, 10(3): E807-E817.
|
26. |
Ruggeri M, Signorini A, Caravaggio S. Casirivimab and imdevimab: cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19. PLoS One, 2023, 18(2): e0279022.
|
27. |
Savinkina A, Paltiel AD, Ross JS, et al. Population-level strategies for nirmatrelvir/ritonavir prescribing-a cost-effectiveness analysis. Open Forum Infect Dis, 2022, 9(12): ofac637.
|
28. |
Park M, Tan KB, Vasoo S, et al. Estimated health outcomes and costs associated with use of monoclonal antibodies for prevention or mitigation of SARS-CoV-2 infections. JAMA Netw Open, 2022, 5(4): e225750.
|
29. |
Chow R, Im J, Chiu N, et al. The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis. PLoS One, 2021, 16(6): e0253576.
|
30. |
Pan H, Peto R, Henao-Restrepo A M, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med, 2021, 384(6): 497-511.
|
31. |
Dejmek M, Konkoľová E, Eyer L, et al. Non-nucleotide RNA-dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication. Viruses, 2021, 13(8): 1585.
|
32. |
WHO. Therapeutics and COVID-19: living guideline. 2022.
|